For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Interleukin 17A (IL-17A) is the founding member of a group of cytokines called the IL-17 family. The other members are IL-17B, C, D, E, and F. Mature mouse or rat IL-17A is a glycosylated homodimer formed of two 133 amino acid subunits. IL17A is produced by a subset of T helper cells. It is a proinflammatory cytokine that enhances T cell priming and stimulates macrophages, fibroblasts, endothelial and epithelial cells to produce mediators of inflammation like IL-1, IL-6, and TNFα. It is also critical for neutrophil activation and migration, and induces IL-8, a key chemokine for neutrophils. IL-17 has been involved in the proinflammatory patterns associated with joint inflammation and rheumatoid arthritis in mouse and human models and may be a novel therapeutic target for the treatment of these diseases.
AlphaLISA® technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Autoimmunity, Inflammation|
|Unit Size||500 assay points|
Immunoassays are a mainstay for the quantification of a variety of biomolecular analytes in drug discovery, drug development, and life sciences research. AlphaLISA® proves advantageous to ELISAs, offering a novel, homogenous immunoassay technology that eliminates wash steps. Using the JANUS® Automated Workstation in combination with AlphaLISA provides a solution to easily preparing assays that can be tailored to the needs of the laboratory. Moreover, the JANUS workstation can be easily set-up to process different assay types in a multi-user, multi-assay environment, thus providing a flexible automation solution.
In this application note, we demonstrate the performance of the JANUS Workstation in automating four AlphaLISA cytokine assays: IL1b, TNFa, IL17, IFNg.
Alpha (Amplified Luminescent Proximity Homogeneous Assay) technology is a bead-based, no-wash alternative to traditional ELISAs. Instead of detection with an HRP substrate, the Alpha assay signal is generated by the excitation of an Eu+-coated bead that has been conjugated to the detection antibody.
Alpha technology offers a simple, straight forward workflow. No wash needed!
Download this application note to see how no-wash AlphaLISA® technology provides a more-convenient alternative to ELISA for quantitation of biomarkers in complex sample types, including tissue, serum, and plasma.
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.